focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 78.10
Bid: 0.00
Ask: 80.70
Change: -1.10 (-1.39%)
Spread: 1.10 (1.382%)
Open: 79.00
High: 79.80
Low: 78.10
Prev. Close: 79.20
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kerry Strategic Update – Capital Markets Day

13 Oct 2021 07:00

RNS Number : 8674O
Kerry Group PLC
13 October 2021
 

 

Date: 13 October 2021

 

LEI: 635400TLVVBNXLFHWC59

 

 

KERRY GROUP

 

Kerry Presents its Strategic Update at Virtual Capital Markets Day

Kerry Group plc ("Kerry"), the global taste & nutrition company, today presents its updated strategy, mid-term financial targets for the period 2022-2026, and sustainability commitments for 2030.

CEO Edmond Scanlon commented "We have made significant strategic progress in recent years, as we continue to evolve our business as the world's leading taste & nutrition partner for the food, beverage and pharmaceutical markets. We have a truly unique business with strong leadership positions, aligned to today's consumer demands and customer needs. Today's update is the next evolution of Kerry, as we strive to create value for our customers every day, by solving their complex challenges with differentiated solutions. This supports our vision to be our customers' most valued partner, creating a world of sustainable nutrition". The updated strategic framework continues to reflect Kerry's overarching strategic priorities of Taste, Nutrition and Emerging Markets. The Group's annual revenue volume growth target has been updated to 4-6% on average across the plan, supported by the key growth platforms of Authentic Taste, Plant-Based, Food Waste, and Health & Bio-Pharma.

The Group has set an EBITDA¹ margin target of 18%+ by 2026. This will be underpinned by expanding the EBITDA¹ margin in Taste & Nutrition to 20%+. The key pillars of Kerry's margin expansion target are enhanced portfolio mix, operating leverage, and operational efficiencies, partially offset by reinvestment for growth initiatives. As part of the operational efficiencies pillar, the Group is today announcing its Accelerate Operational Excellence Transformation programme, beginning in 2022 and running until 2024. The programme will focus on manufacturing and supply chain excellence, with an investment of approximately €120m over the period, delivering a full annual recurring benefit of c. €70m per annum from 2025, following the completion of the programme. Included within the Group's average mid-term targets are cash conversion of 80%+ and Return on Average Capital Employed of 10-12%.

As part of Kerry's Beyond the Horizon sustainability strategy, the company also announces an enhancement of its targets. Kerry is increasing its target for scope 1 and 2 emissions reduction from 33% to 55% by 2030, aligning with the most ambitious goal of the Paris Agreement. As part of its broader Diversity, Inclusion and Belonging strategy, Kerry is extending its commitment to equal gender representation across all senior management roles by 2030.

The virtual Capital Markets Day will begin at 1pm Irish time and will run until approximately 4:30pm. Access to the webcast will be available on the Investor Relations section of the Kerry Group website on www.kerrygroup.com/investors. A replay of the webcast and slides will be available on the Group's website later in the day.

About Kerry Group

Kerry is the world's leading taste and nutrition partner for the food, beverage and pharmaceutical markets. We innovate with our customers to create great tasting products, with improved nutrition and functionality, while ensuring better impact for the planet. Our leading consumer insights, global RD&A team of 1,100+ food scientists and extensive global footprint enable us to solve our customers' complex challenges with differentiated solutions. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and to reach over 2 billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerrygroup.com.

Disclaimer: Forward Looking Statements

This Announcement contains forward looking statements which reflect management expectations based on currently available data. However actual results may differ materially from those expressed or implied by these forward looking statements. These forward looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update any forward looking statement, whether as a result of new information, future events or otherwise. No statement in the Announcement is intended as a profit forecast or a profit estimate.

 

¹EBITDA represents profit before finance income and costs, income taxes, depreciation (net of capital grant amortisation), intangible asset amortisation and non-trading items (net of related tax).

 

CONTACT INFORMATION

 

 

 

 

 

Investor Relations

 

 

Marguerite Larkin, Chief Financial Officer

 

 

+353 66 7182292 | investorrelations@kerry.ie

 

 

 

 

 

William Lynch, Head of Investor Relations

 

 

+353 66 7182292 | investorrelations@kerry.ie

 

 

 

 

 

Media

 

 

Catherine Keogh, Chief Corporate Affairs & Brand Officer

 

 

+353 45 930188 | corpaffairs@kerry.com

 

 

 

 

 

Website

 

 

www.kerrygroup.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAEEAFAAFFAA
Date   Source Headline
20th Jun 202210:23 amRNSHolding(s) in Company
1st Jun 202210:03 amRNSTotal Voting Rights
3rd May 202212:57 pmRNSTotal Voting Rights
28th Apr 20224:32 pmRNSDirectorate Change
28th Apr 20224:29 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 Interim Management Statement 2022
4th Apr 20221:42 pmRNSStatement re Russian and Belarus Operations
1st Apr 202211:22 amRNSTotal Voting Rights
25th Mar 202212:55 pmRNSNotice of AGM
16th Mar 20221:50 pmRNSHolding(s) in Company
16th Mar 20221:39 pmRNSDirector/PDMR Shareholding
15th Mar 20224:45 pmRNSDirector/PDMR Shareholding
11th Mar 20224:03 pmRNSDirector/PDMR Shareholding
11th Mar 20223:59 pmRNSDirector/PDMR Shareholding
11th Mar 20223:55 pmRNSDirector/PDMR Shareholding
11th Mar 202212:13 pmRNSAnnual Financial Report
1st Mar 20229:50 amRNSTotal Voting Rights
25th Feb 20223:14 pmRNSDirector/PDMR Shareholding
16th Feb 20227:00 amRNSPreliminary Statement of Results 31 December 2021
15th Feb 202211:29 amRNSNotice of Results and AGM
15th Feb 20227:00 amRNSKerry – strategic biotechnology acquisitions
1st Feb 20222:21 pmRNSTotal Voting Rights
4th Jan 20223:00 pmRNSBlock listing Interim Review
4th Jan 202212:00 pmRNSTotal Voting Rights
13th Dec 202110:31 amRNSDirectorate Change
9th Dec 202112:17 pmRNSDirector/PDMR Shareholding
1st Dec 202112:26 pmRNSTotal Voting Rights
29th Nov 20211:28 pmRNSDirector/PDMR Shareholding
24th Nov 20215:41 pmRNSKerry - EUR750m Sustainability-Linked Notes
1st Nov 202111:20 amRNSTotal Voting Rights
27th Oct 20217:00 amRNSQ3 Interim Management Statement 2021
13th Oct 20217:00 amRNSKerry Strategic Update – Capital Markets Day
1st Oct 20219:20 amRNSTotal Voting Rights
27th Sep 20217:00 amRNSKerry Completes Sale of Meats & Meals Business
14th Sep 20217:00 amRNSKerry completes acquisition of Niacet
2nd Sep 202111:54 amRNSHolding(s) in Company
1st Sep 202111:22 amRNSHolding(s) in Company
1st Sep 202111:02 amRNSTotal Voting Rights
18th Aug 20214:11 pmRNSDirector/PDMR Shareholding
6th Aug 20214:20 pmRNSHolding(s) in Company
3rd Aug 202111:17 amRNSTotal Voting Rights
30th Jul 20217:00 amRNSKerry Group Interim Management Report 2021
8th Jul 20217:00 amRNSResult of public tender offer for Biosearch Life
1st Jul 202112:22 pmRNSBlock listing Interim Review
1st Jul 202110:00 amRNSTotal Voting Rights
28th Jun 20215:27 pmRNSHolding(s) in Company
25th Jun 20212:52 pmRNSDirector/PDMR Shareholding
25th Jun 202112:49 pmRNSDirector/PDMR Shareholding
21st Jun 20217:00 amRNSKerry agrees to acquire Niacet for EUR853m
18th Jun 20217:00 amRNSKerry Agrees sale of Foods Meats & Meals business

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.